Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53 -Mutated Diffuse Large B-Cell Lymphoma

PURPOSE: -mutant DLBCL. METHODS: Clinical and molecular data for 3,091 patients were derived from 10 cohorts of patients with newly diagnosed DLBCL treated with frontline rituximab-based immunochemotherapy regimens. Targeted or whole-exome/whole-genome sequencing was available for all patients. Bulk RNA-seq was analyzed for 591 patient samples. The primary outcome measures were progression-free survival (PFS) and overall survival (OS). RESULTS: -mutant DLBCL and abrogated the deleterious impact of high VAF, irrespective of patients' age. CONCLUSION: -mutant DLBCL is dependent on intrinsic features, such as VAF, and modulated by co-occurring genomic lesions or lymphoma cell-intrinsic or microenvironmental expression patterns.